Alto Neuroscience (ANRO) Amortizatization of Intangibles (2023 - 2026)
Alto Neuroscience's (ANRO) quarterly Amortizatization of Intangibles came in at $200000.0 in Q1 2026, up 5.26% year-on-year from $190000.0 in Q1 2025, and up 1.52% quarter-over-quarter from $197000.0 in Q4 2025.
Alto Neuroscience (ANRO) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Alto Neuroscience has disclosed Amortizatization of Intangibles across 4 years of filings, most recently posting $200000.0 for Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $200000.0, up 5.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $784000.0 (up 72.31% YoY), and the FY2025 annual result was $774000.0, up 129.67% from the prior year.
- Amortizatization of Intangibles came in at $200000.0 for Q1 2026 at Alto Neuroscience, up from $197000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $211000.0 in Q4 2024 to a low of $54000.0 in Q2 2024.
- The 4-year median for Amortizatization of Intangibles is $132500.0 (2023), against an average of $132583.3.
- Across the five-year window, Amortizatization of Intangibles decreased 21.74% in 2024 and soared 255.56% in 2025, its largest moves.
- Alto Neuroscience's Amortizatization of Intangibles stood at $71000.0 in 2023, then jumped by 197.18% to $211000.0 in 2024, then slipped by 6.64% to $197000.0 in 2025, then advanced by 1.52% to $200000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $200000.0 (Q1 2026), $197000.0 (Q4 2025), and $195000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Alto Neuroscience | 643.06 Mn | 379.30 Mn | - | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 197,000.00 |
| Dec 31, 2025 | 197,000.00 |
| Sep 30, 2025 | 195,000.00 |
| Sep 30, 2025 | 195,000.00 |
| Jun 30, 2025 | 192,000.00 |
| Jun 30, 2025 | 192,000.00 |
| Mar 31, 2025 | 190,000.00 |
| Mar 31, 2025 | 190,000.00 |
| Dec 31, 2024 | 211,000.00 |
| Dec 31, 2024 | 211,000.00 |
| Jun 30, 2024 | 54,000.00 |
| Jun 30, 2024 | 54,000.00 |
| Mar 31, 2024 | 72,000.00 |
| Mar 31, 2024 | 72,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Dec 31, 2023 | 71,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Sep 30, 2023 | 65,000.00 |